Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stenzl

Showing results (751-760 of 819) with videos related to

Pageof 82
Sort By:
Nature|October 14, 2008
Generation of pluripotent stem cells from adult human testisSabine Conrad, Markus Renninger, Jörg Hennenlotter, et al.
Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society|December 16, 2014
Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose TreosulfanM Vogelhuber, S Feyerabend, A Stenzl, et al.
Urologic Oncology|October 23, 2022
Discriminative capacity of guideline recommendations in the assessment of patients with asymptomatic microhematuriaEva Charlotte Kuckuck, Jörg Hennenlotter, Tilman Todenhöfer, et al.
European Urology|July 8, 2008
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsyAlexander Haese, Alexandre de la Taille, Hendrik van Poppel, et al.
Urologic Oncology|February 25, 2024
Simulation of the effects of molecular urine markers in follow-up of patients with high-risk non-muscle invasive bladder cancerNatalya Benderska-Söder, Thorsten Ecke, Lisa Kleinlein, et al.
The Lancet. Oncology|March 12, 2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trialKim N Chi, Celestia S Higano, Brent Blumenstein, et al.
Clinical and Translational Medicine|June 9, 2022
Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinomaAnna Reustle, Lena-Sophie Menig, Patrick Leuthold, et al.
World Journal of Urology|January 27, 2019
SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancerJeffrey J Leow, Jens Bedke, Karim Chamie, et al.
Cancers|June 2, 2021
Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)Philip Zeuschner, Sebastian Hölters, Michael Stöckle, et al.
European Urology|January 14, 2015
Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus PanelTimothy G Wilson, Khurshid Guru, Raymond C Rosen, et al.
Pageof 82

Showing results (751-760 of 819) with videos related to

Sort By:
Pageof 82
Nature|October 14, 2008
Generation of pluripotent stem cells from adult human testisSabine Conrad, Markus Renninger, Jörg Hennenlotter, et al.
Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society|December 16, 2014
Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose TreosulfanM Vogelhuber, S Feyerabend, A Stenzl, et al.
Urologic Oncology|October 23, 2022
Discriminative capacity of guideline recommendations in the assessment of patients with asymptomatic microhematuriaEva Charlotte Kuckuck, Jörg Hennenlotter, Tilman Todenhöfer, et al.
European Urology|July 8, 2008
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsyAlexander Haese, Alexandre de la Taille, Hendrik van Poppel, et al.
Urologic Oncology|February 25, 2024
Simulation of the effects of molecular urine markers in follow-up of patients with high-risk non-muscle invasive bladder cancerNatalya Benderska-Söder, Thorsten Ecke, Lisa Kleinlein, et al.
The Lancet. Oncology|March 12, 2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trialKim N Chi, Celestia S Higano, Brent Blumenstein, et al.
Clinical and Translational Medicine|June 9, 2022
Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinomaAnna Reustle, Lena-Sophie Menig, Patrick Leuthold, et al.
World Journal of Urology|January 27, 2019
SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancerJeffrey J Leow, Jens Bedke, Karim Chamie, et al.
Cancers|June 2, 2021
Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)Philip Zeuschner, Sebastian Hölters, Michael Stöckle, et al.
European Urology|January 14, 2015
Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus PanelTimothy G Wilson, Khurshid Guru, Raymond C Rosen, et al.
Pageof 82